Cochrane · systematic review · CD007929
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
Tattersall, A, Ryan, N, Wiggans, AJ, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
30
current version
GRADE rated
18
No studies
11
Included studies
NR
No studies 11 · 36.7%Ungraded 1 · 3.3%Very low 5 · 16.7%Low 6 · 20%Moderate 5 · 16.7%High 2 · 6.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsSummary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone
Population: newly‐diagnosed EOC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone | no estimate extracted | NR | No studies |
Overall survival ‐ not reported Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone | no estimate extracted | NR | No studies |
Progression‐free survival (PFS) Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone | HR 0.82 [0.49, 1.38] | 2 studies · 1564 participants | Very low Downgraded: imprecision, inconsistency, indirectness |
Quality of life (QoL) Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone | no estimate extracted | 1 study · 744 participants | Moderate Downgraded: imprecision, indirectness |
Any severe adverse event (grade 3 or higher) (G3+ SevAE) Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone | RR 1.13 [1.07, 1.2] | 2 studies · 1549 participants | High |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy compared with placebo (maintenance therapy)
Population: newly‐diagnosed EOC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy) | no estimate extracted | NR | No studies |
Overall survival (OS) Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy) | HR 0.81 [0.59, 1.13] | 2 studies · 1124 participants | Moderate Downgraded: imprecision |
Progression‐free survival (PFS) Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy) | HR 0.42 [0.19, 0.92] | 2 studies · 1124 participants | Low Downgraded: imprecision, inconsistency |
Quality of Life (QoL) Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy) | no estimate extracted | 1 study · 362 participants | Moderate Downgraded: imprecision |
Any severe adverse event (grade 3 or higher) (G3+ SevAE ) Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy) | RR 2.87 [1.65, 4.99] | 2 studies · 1118 participants | Very low Downgraded: imprecision, inconsistency |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy
Population: platinum‐sensitive recurrent EOC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy | no estimate extracted | NR | No studies |
Overall survival (OS) Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy | HR 0.95 [0.62, 1.47] | 2 studies · 331 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Progression‐free survival (PFS) Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy | HR 0.88 [0.56, 1.38] | 3 studies · 739 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Quality of Life (QoL) Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy | no estimate extracted | 1 study · 229 participants | Low Downgraded: risk of bias, imprecision |
Any severe adverse event (grade 3 or higher) (G3+ SevAE) Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy | RR 1.06 [0.8, 1.39] | 1 study · 254 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy)
Population: platinum‐sensitive recurrent EOC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo after chemotherapy (maintenance therapy) | no estimate extracted | NR | No studies |
Overall survival (OS) Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo after chemotherapy (maintenance therapy) | HR 0.88 [0.65, 1.2] | 2 studies · 560 participants | Moderate Downgraded: imprecision |
Progression‐free survival (PFS) Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo after chemotherapy (maintenance therapy) | HR 0.34 [0.28, 0.42] | 4 studies · 1677 participants | High |
Quality of Life ‐ European Quality of Life 5‐dimensionsquestionnaire ‐ Participants with BRCA mutation (QoL) Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo after chemotherapy (maintenance therapy) | no estimate extracted | 1 study · 339 participants | Moderate Downgraded: imprecision |
Any severe adverse event (grade 3 or higher) (G3+ SevAE) Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo after chemotherapy (maintenance therapy) | RR 2.62 [1.85, 3.72] | 4 studies · 1665 participants | Low Downgraded: imprecision, inconsistency |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone
Population: platinum‐sensitive recurrent EOC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone | no estimate extracted | NR | No studies |
Overall survival (OS) Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone | no estimate extracted | 1 study · 1 participants | Ungraded |
Progression‐free survival (PFS) Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone | HR 1.02 [0.69, 1.51] | 1 study · 75 participants | Very low Downgraded: risk of bias, imprecision |
Quality of Life ‐ not reported Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone | no estimate extracted | NR | No studies |
Any severe adverse event (grade 3 or higher) (G3+ SevAE) Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone | RR 1.14 [0.89, 1.47] | 1 study · 156 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy
Population: platinum‐resistant recurrent EOC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy | no estimate extracted | NR | No studies |
Overall survival ‐ not reported Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy | no estimate extracted | NR | No studies |
Progression‐free survival ‐ not reported Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy | no estimate extracted | NR | No studies |
Any severe adverse events (grade 3 or higher) (G3+ SevAE) Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy | RR 1.16 [0.79, 1.7] | 1 study · 100 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Quality of Life ‐ not reported Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy | no estimate extracted | NR | No studies |